ReviewAmerican journal of clinical and experimental urology2026
Whole-mount histopathology as spatial ground truth for artificial intelligence in prostate cancer: a structured narrative review of techniques, models, and translational gaps.
Review in American journal of clinical and experimental urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is spatially heterogeneous, multifocal, and architecturally varied. Conventional biopsy and step-sectioned histopathology fragment the gland. This limits accurate assessment of dominant-lesion identity, tumor volume, multifocality, extraprostatic extension, seminal vesicle invasion, and surgical margin status. Whole-mount histopathology (WMH) preserves the prostate as a continuous cross-sectional unit and is increasingly used as the reference standard for radiology-pathology correlation and for validating artificial-intelligence (AI) models.
objectiveThis structured narrative review synthesizes evidence on the joint use of WMH and AI in prostate cancer pathology. For each clinical question, we examine what spatial information WMH preserves, what AI methods extract from that information, where the joint approach has been validated, and where validation gaps remain. The questions are index-lesion identification, tumor-volume estimation, multifocality, extraprostatic extension, seminal vesicle invasion, surgical margin assessment, Gleason grading, magnetic resonance imaging (MRI)-pathology registration, and surgical quality assurance.
findingsWMH improves index-lesion identification, volumetric reproducibility, and margin clarity, and provides a high-fidelity reference standard for training prostate-AI models. Registered to the patient's presurgical MRI, these whole-mount labels have also been used to train preoperative tools and have been studied in research cohorts for focal-therapy margin definition and extraprostatic-extension prediction, extending the value of WMH beyond retrospective staging. AI systems built on WMH show improved performance for tumor detection and Gleason classification. Most reported results, however, lack external validation, reporting against established medical-AI standards, and demonstrated robustness across scanners, stains, and patient populations. WMH is itself an imperfect ground truth, subject to orientation, registration, and interobserver variability that AI models inherit. IMPLICATIONS: WMH-grounded AI is a credible translational route, but routine adoption requires standardized large-format scanning, shared annotation protocols, external validation, and regulatory clearance for autonomous use. We identify field priorities, including cross-institutional WMH datasets, domain-shift mitigation, bias auditing, and reimbursement parity with AI-augmented radiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.